Ingelheim, Germany, 9 April 2019 – Boehringer Ingelheim launches Arti-Cell^® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’.

Equine lameness is truly common and impacts horse performance as well as equine welfare¹. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.

Arti-Cell^® Forte is a groundbreaking first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell^® Forte comes in an ultra-low frozen ready-to-use presentation.

Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell^® Forte was specifically designed for horses to provide a convenient and long-term² solution for recurrent lameness